Consilium MedicumConsilium Medicum2075-17532542-2170Consilium Medicum92104Research ArticleNesteroidnye protivovospalitel'nye preparaty v lechenii osteoartrozaChichasovaN. V-1502200682424528122021Copyright © 2006, Consilium Medicum2006остеоартрозбольболевой синдромнестероидные противовосплительные препаратыингибиторы ЦОГ-2мелоксикам[Lawrence R.C, Brummer J.M, Bier F. Osteoarthritis prevalence in the population and relationship between symptoms and x - ray changes. Ann Rheum Dis 1966; 25: 1-24.][Pavelka K, Gatterova J, Olejarova M et al. Glucosamine Sulfate use and delay of progression of knee osteoarthritis. Arch Int Med 2002; 162: 2113-22.][Алексеева Л.И. Современные подходы к лечению остеоартроза. РМЖ. 2003; 11 (4): 201-5.][Reginster J.Y, Deroisy R, Rovati L.C et al. Long - term effects of glucosamine sulphate on osteoarthritis progression: a randomized, placebo - controlled clinical trial. Lancet 2001; 357: 251-6.][Haskisson E.C. Clinical aspects of chondroprotection. Sem Arthr Rheum 1990; 19: 30-2.][Jouzeau J.Y, Terlain B, Abid A et al. Cyclo - oxigenase isoenzymes: how recent findings affect thinking about nonsteroidal anti - inflammatory drugs. Drugs 1997; 53: 563-82.][Armstrong C.P, Blower A.L. Non - steroidal anti - inflammatory drugs and life threatening complication of peptic ulceration. Gut 1987; 28: 527-32.][Singh G, Ramey D.R, Morfield D et al. Gastrointestinal tract complications on nonsteroidal anti - inflammatory drug treatment in rheumatoid arthritis. Arch Intern Med 1996; 156: 1530-6.][Каратеев А.Е., Коновалова Н.Н., Литовченко А.А. и др. НПВП-ассоциированное заболевание желудочно - кишечного тракта при ревматизме в России. Клин. мед. 2005.][Савенков М.П., Бродская С.А., Иванов С.Н., Судакова Н.И. Влияние нестероидных противовоспалительных средств на антигипертензивный эффект ингибиторов АПФ. РМЖ. 2003; 19: 1056-9.][Rashad S, Revell P, Hemingway A et al. Effect of non - steroidal anti - inflammatory drugs on the course of osteoarthritis. Lancet 1989; i: 519-22.][Yocum D, Fleishmann R, Dalgin P et al. Safety and efficacy of meloxicam in the treatment of osteoarthritis: a 12-week, double - blind, multiple dose, placebo - controlled trial. The Meloxicam Osteoarthritis Investigators. Arch Int Med 2000; 160: 2947-54.][Martin R.M, Biswas P, Mann R.D. The incidence of adverse events and risk factors for upper gastrointestinal disorders associated with meloxicam use amongst 19087 patients in general practice in England: cohort study. Br J Clin Pharmacol 2000; 50: 35-42.][Lapisque F, Vergne P, Jouzeau J-I et al. Articular diffusion of meloxicam after a single oral dose: relationship to cyclo - oxygenase inhibition in synovial cells. Clin Pharmokinet 2000; 39: 369-82.][Zeidler H, Kaltwasser J.P, Leonard J.P et al. Prescription and tolerability of meloxicam in day - to - day practice: postmarceting observational cohort study of 13307 patients. J Clin Rheum 2002; 8: 305-15.][Singh G, Triadafilopoulos G. Epidemiology of NSAIDs indused gastrointestinal complications. J Rheum 1999; 26 (Suppl. 56): 18-24.][Davies N.M, Skjodt N.M. Clinical pharmacokinetics of meloxicam: a cyclo - oxygenase-2 preferential nonsteroidal anti i nflammatory drug. Clin Pharmacokinet 1999; 36: 115-26.][Combe B, Velicitat P, Garson N, Bluhmki E. Comparison of intramuscular and oral meloxicam in rheumatoid arthritis patients. Inflamm Res 2001; 50 (Suppl. 1): S10-16.][Цветкова Е.С. Эффективность и переносимость ступенчатой терапии мелоксикамом (мелоксикамом) при ревматических заболеваниях. Тер. архив. 2004; 12: 78-80.][Алексеев В.В. Применение мелоксикама в лечении люмбоишиалгического синдрома. РМЖ. 2003; 7 (11): 416-8.][Vidal L, Kneer W, Baturone M et al. Meloxicam in acute episodes of soft - tissue rheumatism of the shoulder. Inflam Res 2001; 50 (Suppl. 1): S24-29.][Singh G. Meloxicam does not increase the risk of acute myocardial infarction, congestive heart failure, edema or hypertension compared to NSAIDs: results from a pooled analysis of 27039 patients [abstract]. Eur Congress of Rheumatology, Prague, 2001, June 13-16.][Altman R, Luciardi H.L, Muntaner J et al. Efficacy assessment of meloxicam, a preferential cyclooxigenase-2 inhibitor, in acute coronary syndromes without ST-segment elevation: The Nonsteroidal Anti-Inflammatory Drugs in Instable Angina Treatment -2 (NUT-2) Pilot Study. Circulation 2002; 196: 191-5.]